Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis
ObjectiveThis meta-analysis evaluated pembrolizumab monotherapy and combination therapy’s efficacy and safety in recurrent or advanced endometrial cancer (EC).MethodsWe utilized PubMed, Embase, Cochrane Library, and Web of Science databases to identify clinical trials that were used to search litera...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1511301/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542381987069952 |
|---|---|
| author | Biqiong Pan Xiaojun Lai Jiefang Lu Xiaoyan Bao Zengke Fan Jie Sun |
| author_facet | Biqiong Pan Xiaojun Lai Jiefang Lu Xiaoyan Bao Zengke Fan Jie Sun |
| author_sort | Biqiong Pan |
| collection | DOAJ |
| description | ObjectiveThis meta-analysis evaluated pembrolizumab monotherapy and combination therapy’s efficacy and safety in recurrent or advanced endometrial cancer (EC).MethodsWe utilized PubMed, Embase, Cochrane Library, and Web of Science databases to identify clinical trials that were used to search literature from July 2013 to July 2023 to evaluate the efficacy and safety of pembrolizumab in patients with advanced EC. Eight studies with 2,742 patients were included. Outcomes were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), complete remission (CR), and adverse events (AEs); a subgroup analysis was carried out based on combination treatment regimens. Quality assessment of the included studies was conducted using the Cochrane Risk of Bias Tool, the Newcastle–Ottawa Scale (NOS), and the Joanna Briggs Institute (JBI) critical appraisal checklist.ResultsPembrolizumab reduced progression risk [hazard ratio (HR): 0.53; 95% confidence interval (CI): 0.44, 0.63; p < 0.00001] and death risk when combined with lenvatinib (HR: 0.67; 95% CI: 0.59, 0.76; p < 0.00001). Pembrolizumab monotherapy and lenvatinib combination achieved higher ORR (OR: 3.61; 95% CI: 2.12, 6.13; p < 0.00001) and CR rates (OR: 2.7; 95% CI: 1.59, 4.57; p < 0.05) than controls. Single-arm studies: 8% CR and 4% PR in pembrolizumab-treated patients. Pooled AE incidence: 86%, with 43% grade 3/4. Two randomized controlled trials (RCTs) found that the pembrolizumab group had a higher incidence of grade 3 or 4 AEs compared to the control group (OR: 2.23; 95% CI: 1.23, 4.04; p = 0.008).ConclusionPembrolizumab monotherapy or combination significantly improves survival in recurrent or advanced EC and has manageable toxicity albeit with a relatively high incidence of treatment-related AEs. |
| format | Article |
| id | doaj-art-7c2a37c9b9604927a2031c5fc99bca35 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-7c2a37c9b9604927a2031c5fc99bca352025-02-04T05:28:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011410.3389/fonc.2024.15113011511301Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysisBiqiong Pan0Xiaojun Lai1Jiefang Lu2Xiaoyan Bao3Zengke Fan4Jie Sun5Department of Gynecology and Obstetrics, Lishui People’s Hospital, Lishui, Zhejiang, ChinaDepartment of Gynecology and Obstetrics, Lishui People’s Hospital, Lishui, Zhejiang, ChinaDepartment of Gynecology and Obstetrics, Lishui People’s Hospital, Lishui, Zhejiang, ChinaDepartment of Gynecology and Obstetrics, Lishui People’s Hospital, Lishui, Zhejiang, ChinaDepartment of Gynecology and Obstetrics, Lishui People’s Hospital, Lishui, Zhejiang, ChinaDepartment of Anorectal Surgery, Lishui People’s Hospital, Lishui, Zhejiang, ChinaObjectiveThis meta-analysis evaluated pembrolizumab monotherapy and combination therapy’s efficacy and safety in recurrent or advanced endometrial cancer (EC).MethodsWe utilized PubMed, Embase, Cochrane Library, and Web of Science databases to identify clinical trials that were used to search literature from July 2013 to July 2023 to evaluate the efficacy and safety of pembrolizumab in patients with advanced EC. Eight studies with 2,742 patients were included. Outcomes were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), complete remission (CR), and adverse events (AEs); a subgroup analysis was carried out based on combination treatment regimens. Quality assessment of the included studies was conducted using the Cochrane Risk of Bias Tool, the Newcastle–Ottawa Scale (NOS), and the Joanna Briggs Institute (JBI) critical appraisal checklist.ResultsPembrolizumab reduced progression risk [hazard ratio (HR): 0.53; 95% confidence interval (CI): 0.44, 0.63; p < 0.00001] and death risk when combined with lenvatinib (HR: 0.67; 95% CI: 0.59, 0.76; p < 0.00001). Pembrolizumab monotherapy and lenvatinib combination achieved higher ORR (OR: 3.61; 95% CI: 2.12, 6.13; p < 0.00001) and CR rates (OR: 2.7; 95% CI: 1.59, 4.57; p < 0.05) than controls. Single-arm studies: 8% CR and 4% PR in pembrolizumab-treated patients. Pooled AE incidence: 86%, with 43% grade 3/4. Two randomized controlled trials (RCTs) found that the pembrolizumab group had a higher incidence of grade 3 or 4 AEs compared to the control group (OR: 2.23; 95% CI: 1.23, 4.04; p = 0.008).ConclusionPembrolizumab monotherapy or combination significantly improves survival in recurrent or advanced EC and has manageable toxicity albeit with a relatively high incidence of treatment-related AEs.https://www.frontiersin.org/articles/10.3389/fonc.2024.1511301/fullpembrolizumabmonotherapyendometrial cancermeta-analysisefficacy and safety |
| spellingShingle | Biqiong Pan Xiaojun Lai Jiefang Lu Xiaoyan Bao Zengke Fan Jie Sun Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis Frontiers in Oncology pembrolizumab monotherapy endometrial cancer meta-analysis efficacy and safety |
| title | Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis |
| title_full | Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis |
| title_short | Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis |
| title_sort | efficacy and safety of pembrolizumab in patients with advanced endometrial cancer a systematic review and meta analysis |
| topic | pembrolizumab monotherapy endometrial cancer meta-analysis efficacy and safety |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1511301/full |
| work_keys_str_mv | AT biqiongpan efficacyandsafetyofpembrolizumabinpatientswithadvancedendometrialcancerasystematicreviewandmetaanalysis AT xiaojunlai efficacyandsafetyofpembrolizumabinpatientswithadvancedendometrialcancerasystematicreviewandmetaanalysis AT jiefanglu efficacyandsafetyofpembrolizumabinpatientswithadvancedendometrialcancerasystematicreviewandmetaanalysis AT xiaoyanbao efficacyandsafetyofpembrolizumabinpatientswithadvancedendometrialcancerasystematicreviewandmetaanalysis AT zengkefan efficacyandsafetyofpembrolizumabinpatientswithadvancedendometrialcancerasystematicreviewandmetaanalysis AT jiesun efficacyandsafetyofpembrolizumabinpatientswithadvancedendometrialcancerasystematicreviewandmetaanalysis |